News About: Pharm. Industry
Celltrion records highest business results ever in 2nd quarterOn the 26th, Celltrion officially announced the 2017 2nd quarter consolidated business results with KRW 246.1 billion sales and KRW 138.3 billion operating profits(operating pro...
|
Chong Kun Dang’s momentum with launch of Sengla after CendomChong Kun Dang(CEO Young-Joo Kim) released ‘Sengla,’ a erectile dysfunction treatment, on the 25th to enlarge its market.
Sildenafil, a Sengla’s main substance, shows excellent...
|
Hanmi creates lineup with Amosartan family, challenging annul KRW 100 million sales
Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kwon) acquired approvals for 2 products of 2-substance combination drug containing the substance of Amosartan, the top sales product. Hanmi is planning to continue the Amosartan...
Huons acquires ‘generic’ approval of 0.9% Sodium Chloride Injection USP 5mL/10mL from U.S. FDAHuons(CEO Gi-An Eom), a subsidiary of Huons Global, announced on the 24th that 0.9% Sodium Chloride Injection USP 5mL/10mL acquired a generic drug approval(ANDA) from the U.S. F...
|
Japanese pharmas stingy in donating money as social contributions
Although Japanese pharmaceutical companies branching in Korea are growing up with product quality and marketing power, they are criticized to neglect social contributions of corporate profit, which are a fundamental d...
Will Pfizer become a new power in health functional food market with new ‘Centrum’?
Pfizer will release 6 new types of ‘Centrum’ to successfully settle in the health function food market.
The consumer healthcare department of Pfizer Pharmaceuticals Korea(CEO/President Dong-Wook Oh) held a press conf...
Japanese pharmas earn 77 out of selling KRW 1,000
Japanese pharmaceutical companies were observed to generate KRW 77 profits by selling products(including goods and merchandises) worth of KRW 1,000 in the Korean market.
Yakup Shinmoon(www.yakup.com) analyzed 2016 au...
Employees at Korean branches of Japanese pharma earn KRW 74 million per employee a year
It was observed employees working at a Korean branch of multinational Japanese pharmaceutical company earns KRW 74 million per employee a year on average, and annual wages of an employee at Takeda Pharmaceuticals Kore...
Japanese pharmas’ rapid growth in Korean pharmaceutical market
Japanese multinational pharmaceutical companies branching in Korea were analyzed to record excellent sales performances last year.
Yakup Shinmoon(www.yakup.com) analyzed 2016 audit reports turned in by Korean branche...
Hanmi Pharm registers ‘Esomezol’
‘Esomezol,’ an acid reflux treatment developed by Hanmi Pharm, was registered at the U.S. Pharmacopeial(USP) for the first time as a Korean pharmaceutical company. Esomezol is the Korea’s first incrementally modified ...
